Effects of Switching from Stavudine to Raltegravir on Subcutaneous Adipose Tissue in HIV-Infected Patients with HIV/HAART-Associated Lipodystrophy Syndrome (HALS). A Clinical and Molecular Study
HIV-1/HAART-associated lipodystrophy syndrome (HALS) has been associated with exposure to stavudine (d4T) through mitochondrial dysfunction. We performed a 48-week study to assess the effects of switching from d4T to raltegravir (RAL) on metabolic and fat molecular parameters of patients with HALS. Forty-two patients with HALS and a median exposure to d4T > 7 years were switched to RAL and followed for 48 weeks. Fasting metabolic tests, HIV RNA, CD4 cell count, and fat measured by DEXA were obtained at baseline and week 48. mtDNA and gene transcripts for PPAR gamma, adiponectin, cytochrome b, Cox IV, TNF alpha, MCP-1 and CD68 were assessed in paired subcutaneous fat tissue biopsies. Lipid parameters, fasting glucose, insulin, and HOMA-IR did not change significantly. Whole body fat (P = 0.0027) and limb fat mass (P<0.0001) increased from baseline. Trunk/limb fat ratio (P = 0.0022), fat mass ratio (P = 0.0020), fat mass index (P = 0.0011) and percent leg fat normalized to BMI (P<0.0001) improved after 48 weeks. Relative abundance of mtDNA, expression of PPAR gamma, adiponectin, Cyt b, and MCP-1 genes increased, whereas Cox IV, TNF alpha, and CD68 did not change significantly from baseline. Switching from d4T to RAL in patients with HALS is associated with an increase in limb fat mass and an improvement in markers of adipocyte differentiation and mitochondrial function in SAT.
References
[1]
Domingo P, Estrada V, López-Aldeguer J, Villarroya F, Martínez E (2012) Fat redistribution syndromes associated with HIV-1 infection and combination antiretroviral therapy. AIDS Rev: 112–123.
[2]
Feeney ER, Mallon PW (2010) Impact of mitochondrial toxicity of HIV-1 antiretroviral drugs on lipodystrophy and metabolic dysregulation. Curr Pharm Des 16: 3339–51. doi: 10.2174/138161210793563482
[3]
Gutierrez MM, Mateo G, Domingo P (2007) Strategies in the treatment of HIV-1-associated adipose redistribution syndromes. Expert Opin Pharmacother 8: 1871–1884. doi: 10.1517/14656566.8.12.1871
[4]
Carr A, Workman C, Smith DE, Hoy J, Hudson J, et al. (2002) Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 288: 207–215. doi: 10.1001/jama.288.2.207
[5]
Moyle GJ, Sabin CA, Cartledge J, Johnson M, Wilkins E, et al. (2006) A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 20: 2043–2050. doi: 10.1097/01.aids.0000247574.33998.03
[6]
Rockstroh JK, Lennox JL, Dejesus E, Saag MS, Lazzarin A, et al. (2011) Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis 53: 807–816. doi: 10.1093/cid/cir510
[7]
Centers for Disease Control (1993) 1993 revised classification system for HIV infection and expanded surveillance for case definition for AIDS among adolescents and adults. MMWR 41 (RR-17): 1–13. doi: 10.1001/jama.269.6.729
[8]
Lemieux S, Prud'homme D, Bouchard C, Tremblay A, Despres JP (1996) A single threshold of waist girth identifies normal-weight and overweight subjects with excess visceral adipose tissue. Am J Clin Nutr 64: 685–693.
[9]
Bonnet E, Delpierre C, Sommet A, Marion-Latard F, Hervé R, et al. (2005) Total body composition by DXA of 241 HIV-negative men and 162 HIV-infected men: proposal of reference values for defining lipodystrophy. J Clin Densitom 8: 287–292. doi: 10.1385/jcd:8:3:287
[10]
Kelly TL, Wilson KE, Heymsfield SB (2009) Dual energy X-Ray absorptiometry body composition reference values from NHANES. PLoS One 4: e7038. doi: 10.1371/journal.pone.0007038
[11]
Nolan D, Hammond E, James I, McKinnon E, Mallal S (2003) Contribution of nucleoside analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antivir Ther 8: 617–626.
[12]
Lichtenstein KA, Ward DJ, Moorman AC, Delaney KM, Young B, et al. (2001) Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 15: 1389–1398. doi: 10.1097/00002030-200107270-00008
[13]
Fontdevila J, Martinez E, Rubio-Murillo JM, Milinkovic A, Serra-Renom JM, Gatell J (2005) A practical classification for the surgical filling of facial lipoatrophy. Antivir Ther 10: L28.
[14]
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285: 2486–2497. doi: 10.1001/jama.285.19.2486
[15]
Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, et al. (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112: 2735–2752. doi: 10.1161/circulationaha.105.169404
[16]
Sugiuchi H, Uji Y, Okabe K (1995) Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulphated alpha-cyclodextrin. Clin Chem 41: 717–723.
C？té HC, Gerschenson M, Walker UA, Miro O, Garrabou G, et al. (2011) Quality assessment of human mitochondrial DNA quantification: MITONAUTS, an international multicentre survey. Mitochondrion 11: 520–527. doi: 10.1016/j.mito.2011.01.011
[19]
Podzamczer D, Ferrer E, Sanchez P, Gatell JM, Crespo M, et al. (2007) Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr 44: 139–147. doi: 10.1097/qai.0b013e31802bf122
[20]
Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, et al. (2004) Efficacy and safety of tenofovir DF vsstavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292: 191–201. doi: 10.1001/jama.292.2.191
[21]
McComsey GA, Daar ES, O′Riordan M, Collier AC, Kosmiski L, et al. (2013) Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202. J Infect Dis 207: 604–611. doi: 10.1093/infdis/jis720
[22]
Mulligan K, Glidden DV, Lama JR, Chariyalertsak S, Guanira-Carranza JV, et al. Effects of Tenofovir/Emtricitabine on body composition in HIV-negative men who have sex with men: whole body DXA results of global iPRex. 19th Conference on Retroviruses and Opportunistic Infections. Seattle, March 5–8, 2012. Abstract 47: 847.
[23]
Venhoff N, Setzer B, Melkaoui K, Walker UA (2007) Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors. Antivir Ther 12: 1075–1085.
[24]
Valantin M, Kolta S, Flandre P, Algarte Genin M, et al. (2012) Body fat distribution in HIV-infected patients treated for 96 weeks with darunavir/ritonavir monotherapy versus darunavir/ritonavir plus nucleoside reverse transcriptase inhibitors: the MONOI-ANRS136 Substudy. HIV Med 13: 505–815. doi: 10.1111/j.1468-1293.2012.01004.x
[25]
Perazella MA (2010) Tenofovir-induced kidney disease: an acquired renal tubular mitochondriopathy. Kidney Int 78: 1060–1063. doi: 10.1038/ki.2010.344
[26]
Mellert W, Kleinschmidt A, Schmidt J, Festl H, Emler S, et al. Infection of human fibroblasts and osteoblast-like cells with HIV-1. AIDS 4: 527–535. doi: 10.1097/00002030-199006000-00006
[27]
Gallego-Escuredo JM, Del Mar Gutierrez M, Diaz-Delfin J, Domingo JC, Mateo MG, et al. (2010) Differential effects of efavirenz and lopinavir/ritonavir on human adipocyte differentiation, gene expression and release of adipokines and pro-inflammatory cytokines. Curr HIV Res 8: 545–553. doi: 10.2174/157016210793499222
[28]
Caron M, Auclairt M, Vissian A, Vigouroux C, Capeau J (2008) Contribution of mitochondrial dysfunction and oxidative stress to cellular premature senescence induced by antiretroviral thymidine analogues. Antivir Ther 13: 27–38.
[29]
Vrouenraets SM, Wit FW, Garcia EF, Huber M, Brinkman K, et al. (2012) Longer prior exposure to zidovudine/lamivudine-containing combination antiretroviral therapy, age, and male gender are each associated with reduced subcutaneous adipose tissue. HIV Clin Trials 13: 103–110. doi: 10.1310/hct1302-103
[30]
Eron JJ, Young B, Cooper DA, Youle M, Dejesus E, et al. (2010) Switch to a raltegravir-based regimenn versus continuation of a lopinavir-ritonavir-based regimenn in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 375: 396–407. doi: 10.1016/s0140-6736(09)62041-9
[31]
Martínez E, Larrousse M, Llibre JM, Gutiérrez F, Saumoy M, et al. (2010) Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS 24: 1697–1707. doi: 10.1097/qad.0b013e32833a608a
[32]
Curran A, Martinez E, Saumoy M, del Rio L, Crespo M, et al. (2012) Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy. AIDS 26: 475–481. doi: 10.1097/qad.0b013e32834f3507
[33]
Lo JC, Kazemi MR, Hsue PY, Martin JN, Deeks SG, et al. (2005) The relationship between nucleoside analogue treatment duration, insulin resistance, and fasting arterialized lactate level in patients with HIV infection. Clin Infect Dis 41: 1335–1340. doi: 10.1086/496981
[34]
Fontas E, van Leth F, Sabin CA, Friis-M？ller N, Rickenbach M, et al. (2004) Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?. J Infect Dis 189: 1056–1074. doi: 10.1086/381783
[35]
Villarroya F, Domingo P, Giralt M (2005) Lipodystrophy associated with highly active anti-retroviral therapy for HIV infection: the adipocyte as a target of anti-retroviral-induced mitochondrial toxicity. Trends Pharmacol Sci 26: 88–93. doi: 10.1016/j.tips.2004.12.005
[36]
Giralt M, Domingo P, Villarroya F (2011) Adipose tissue biology and HIV-infection. Best Pract Res Clin Endocrinol Metab 25: 487–499. doi: 10.1016/j.beem.2010.12.001
[37]
Caron M, Auclair M, Lagathu C, Lombès A, Walker UA, et al. (2004) The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro. AIDS 18: 2127–2136. doi: 10.1097/00002030-200411050-00004
[38]
Jones SP, Qazi N, Morelese J, Lebrecht D, Sutinen J, et al. (2005) Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens. J Acquir Immune Defic Syndr 40: 565–572. doi: 10.1097/01.qai.0000187443.30838.3e
[39]
Lagathu C, Eustace B, Prot M, Frantz D, Gu Y, et al. (2007) Some HIV-antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir Ther 12: 489–500.
[40]
Stankov MV, Lücke T, Das AM, Schmidt RE, Behrens GM (2007) Relationship of mitochondrial DNA depletion and respiratory chain activity in preadipocytes treated with nucleoside reverse transcriptase inhibitors. Antivir Ther 12: 205–216. doi: 10.1128/aac.00914-09
[41]
Perez-Matute P, Pérez-Martínez L, Blanco JR, Oteo JA (2011) Neutral actions of raltegravir on adipogenesis, glucose metabolism and lipolysis in 3T3-L1 adipocytes. Curr HIV Res 9: 174–179. doi: 10.2174/157016211795945278
[42]
Minami R, Yamamoto M, Takahama S, Ando H, Miyamura T, et al. (2011) Comparison of the influence of four classes of HIV antiretrovirals on adipogenic differentiation: the minimal effect of raltegravir and atazanavir. J Infect Chemother 17: 183–188. doi: 10.1007/s10156-010-0101-5
[43]
Mallon PW, Sedwell R, Rogers G, Nolan D, Unemori P, et al. (2008) Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction. J Infect Dis 198: 1794–1803. doi: 10.1086/593179
[44]
Kim MJ, Leclercq P, Lanoy E, Cervera P, Antuna-Puente B, et al. (2007) A 6-month interruption of antiretroviral therapy improves adipose tissue function in HIV-infected patients: the ANRS EP29 Lipostop Study. Antivir Ther 12: 1273–1283.
[45]
Guri AJ, Bassaganya-Riera J (2011) Systemic effects of white adipose tissue dysregulation and obesity-related inflammation. Obesity (Silver Spring) 19: 689–700. doi: 10.1038/oby.2010.230
[46]
Carr A, Hoy J, Pozniak A (2012) The Ethics of Switch/Simplify in Antiretroviral Trials: Non-Inferior or Just Inferior?. PLoS Med 9: e1001240. doi: 10.1371/journal.pmed.1001240
